These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25520521)

  • 1. Accelerating the pace of atherosclerosis research.
    Daugherty A; Tabas I; Rader DJ
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):11-2. PubMed ID: 25520521
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
    Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics: a gene of rare effect.
    Hall SS
    Nature; 2013 Apr; 496(7444):152-5. PubMed ID: 23579660
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical use of genetic typing in human lipid disorders.
    Brown WV; Breslow J; Ballantyne C
    J Clin Lipidol; 2012; 6(3):199-207. PubMed ID: 22658144
    [No Abstract]   [Full Text] [Related]  

  • 6. [PCSK9, from gene to protein: a new actor involved in cholesterol homeostasis].
    Abifadel M; Rabès JP; Boileau C; Varret M
    Med Sci (Paris); 2006 Nov; 22(11):916-8. PubMed ID: 17101087
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monogenic hypercholesterolemias: new genes, new drug targets].
    Mandel'shtam MIu; Vasil'ev VB
    Genetika; 2008 Oct; 44(10):1309-16. PubMed ID: 19062528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 and its modulation.
    Cui CJ; Li S; Li JJ
    Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the first PCSK9 gain of function homozygote.
    Alves AC; Etxebarria A; Medeiros AM; Benito-Vicente A; Thedrez A; Passard M; Croyal M; Martin C; Lambert G; Bourbon M
    J Am Coll Cardiol; 2015 Nov; 66(19):2152-2154. PubMed ID: 26541928
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of atherosclerosis in mice and hamsters without germline genetic engineering.
    Bjørklund MM; Hollensen AK; Hagensen MK; Dagnaes-Hansen F; Christoffersen C; Mikkelsen JG; Bentzon JF
    Circ Res; 2014 May; 114(11):1684-9. PubMed ID: 24677271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family.
    Ruotolo A; Di Taranto MD; D'Agostino MN; Marotta G; Gentile M; Nunziata M; Sodano M; Di Noto R; Del Vecchio L; Rubba P; Fortunato G
    Clin Chem Lab Med; 2014 Aug; 52(8):e175-8. PubMed ID: 24607922
    [No Abstract]   [Full Text] [Related]  

  • 19. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
    Pokharel Y; Virani SS; Ballantyne CM
    Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turning the Titanic.
    Zerhouni EA
    Sci Transl Med; 2014 Jan; 6(221):221ed2. PubMed ID: 24476998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.